Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03524092 · ClinicalTrials.gov registry record · Phase 3
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study of Ulcerative Colitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,177
- Enrollment target
- 20
- Study locations
NCT03524092 is a Phase 3 study of Ulcerative Colitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,177 participants, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT03524092, a Phase 3 study of Ulcerative Colitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,177 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
Conditions Studied
Interventions
- DRUG Placebo SC
- DRUG Mirikizumab IV
- DRUG Mirikizumab SC
Study Locations (20)
Florida
- Direct Helpers Research Center - Hialeah
- Nature Coast Clinical Research, LLC - Inverness
- SIH Research, LLC - Kissimmee
- Research Associates of South Florida, LLC - Miami
- Wellness Clinical Research - Miami Lakes
- Center for Interventional Endoscopy - Orlando
- Clintheory Healthcare - Orlando
- Gastroenterology Associates of Pensacola, PA - Pensacola
- Florida Medical Clinic LLC - Zephyrhills
California
- Valley Gastroenterology - Arcadia
- Care Access Research - Berkeley
- Om Research, LLC - Lancaster
- California Medical Research Associates - Northridge
- Clinical Applications Laboratories, Inc. - San Diego
- UCSF Medical Center at Mission Bay - San Francisco
Arizona
- Dcr-Pi, Pc - Litchfield Park
- Maricopa Integrated Health System - Phoenix
- Physicians Research Group - Tempe
Alabama
- Digestive Health Specialists of the Southeast - Dothan
Georgia
- Digestive Healthcare of Georgia - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,177 participants |
| Start Date | 2018-10-19 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03524092
The ClinicalTrials.gov registry entry for NCT03524092 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,177 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (43% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo SC is the first listed.
NCT03524092 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03524092 about?
NCT03524092 is a clinical study titled "A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
What is the current status of trial NCT03524092?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,177 participants. The study started on 2018-10-19. Estimated completion is 2025-02-17.
What conditions does trial NCT03524092 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT03524092?
The interventions under investigation include: Placebo SC (DRUG), Mirikizumab IV (DRUG), Mirikizumab SC (DRUG).
Who is sponsoring clinical trial NCT03524092?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03524092 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.